MX364912B - Antagonistas / agonistas inversos del receptor canabinoide. - Google Patents

Antagonistas / agonistas inversos del receptor canabinoide.

Info

Publication number
MX364912B
MX364912B MX2015001014A MX2015001014A MX364912B MX 364912 B MX364912 B MX 364912B MX 2015001014 A MX2015001014 A MX 2015001014A MX 2015001014 A MX2015001014 A MX 2015001014A MX 364912 B MX364912 B MX 364912B
Authority
MX
Mexico
Prior art keywords
cannabinoid receptor
receptor antagonists
inverse agonists
disorders
pyrazolines
Prior art date
Application number
MX2015001014A
Other languages
English (en)
Other versions
MX2015001014A (es
Inventor
Mcelroy John
Chorvat Robert
Original Assignee
Jenrin Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenrin Discovery Inc filed Critical Jenrin Discovery Inc
Publication of MX2015001014A publication Critical patent/MX2015001014A/es
Publication of MX364912B publication Critical patent/MX364912B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona pirazolinas diastereoméricas novedosas que son útiles como bloqueantes de los receptores de cannabinoides y composiciones farmacéuticas de estos y métodos para utilizarlos para tratar la obesidad, diabetes, trastornos inflamatorios, trastornos cardiometabólicos, trastornos hepáticos y/o cánceres.
MX2015001014A 2012-07-25 2013-07-25 Antagonistas / agonistas inversos del receptor canabinoide. MX364912B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261675806P 2012-07-25 2012-07-25
US201361787214P 2013-03-15 2013-03-15
US13/950,195 US8680131B2 (en) 2012-07-25 2013-07-24 Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
PCT/US2013/051919 WO2014018695A1 (en) 2012-07-25 2013-07-25 Cannabinoid receptor antagonists/inverse agonists

Publications (2)

Publication Number Publication Date
MX2015001014A MX2015001014A (es) 2015-08-14
MX364912B true MX364912B (es) 2019-05-13

Family

ID=49995474

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001014A MX364912B (es) 2012-07-25 2013-07-25 Antagonistas / agonistas inversos del receptor canabinoide.

Country Status (16)

Country Link
US (6) US8680131B2 (es)
EP (1) EP2877173B1 (es)
JP (1) JP6249534B2 (es)
CN (2) CN104640543A (es)
AU (1) AU2013295741B2 (es)
CA (1) CA2879741C (es)
DK (1) DK2877173T3 (es)
ES (1) ES2771323T3 (es)
HR (1) HRP20200212T1 (es)
HU (1) HUE048386T2 (es)
IL (1) IL236789A (es)
IN (1) IN2015DN01503A (es)
MX (1) MX364912B (es)
PL (1) PL2877173T3 (es)
PT (1) PT2877173T (es)
WO (1) WO2014018695A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680131B2 (en) 2012-07-25 2014-03-25 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
US9837765B2 (en) * 2015-06-25 2017-12-05 Microsoft Technology Licensing, Llc Apparatus for ejecting at least one integrated circuit card
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255093A1 (en) 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
DE60124685T2 (de) 2000-03-23 2007-03-29 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazolderivate mit cb1-antagonistischer aktivität
DE60202270T2 (de) 2001-03-22 2005-05-19 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazolderivate mit cb1-antagonistischer wirkung
UA78523C2 (en) 2001-09-21 2007-04-10 Solvay Pharm Bv 4,5-dihydro-1h-pyrazoie derivatives as cb1 antagonists
AU2002333853B2 (en) 2001-09-21 2006-07-13 Solvay Pharmaceuticals B.V. 4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
CA2651385C (en) 2006-05-05 2015-02-03 John F. Mcelroy Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
US7655685B2 (en) * 2007-11-02 2010-02-02 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
AU2011329636B2 (en) * 2010-11-18 2016-05-19 Jenrin Discovery Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
US8680131B2 (en) * 2012-07-25 2014-03-25 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

Also Published As

Publication number Publication date
US11179370B2 (en) 2021-11-23
DK2877173T3 (da) 2020-02-24
US20210023054A1 (en) 2021-01-28
US20170182004A1 (en) 2017-06-29
CN104640543A (zh) 2015-05-20
AU2013295741A1 (en) 2015-03-12
US10617673B2 (en) 2020-04-14
US9517228B2 (en) 2016-12-13
HRP20200212T1 (hr) 2020-10-16
IL236789A (en) 2017-07-31
JP2015523396A (ja) 2015-08-13
US20140031404A1 (en) 2014-01-30
MX2015001014A (es) 2015-08-14
CN110372593A (zh) 2019-10-25
WO2014018695A1 (en) 2014-01-30
US8680131B2 (en) 2014-03-25
JP6249534B2 (ja) 2017-12-20
US20180353478A1 (en) 2018-12-13
US20160058736A1 (en) 2016-03-03
EP2877173A1 (en) 2015-06-03
AU2013295741B2 (en) 2017-05-04
EP2877173A4 (en) 2016-03-16
US9133127B2 (en) 2015-09-15
PT2877173T (pt) 2020-02-21
PL2877173T3 (pl) 2020-08-10
EP2877173B1 (en) 2019-11-13
ES2771323T3 (es) 2020-07-06
HUE048386T2 (hu) 2020-07-28
IN2015DN01503A (es) 2015-07-03
US9987253B2 (en) 2018-06-05
CA2879741C (en) 2020-09-29
US20140329875A1 (en) 2014-11-06
CA2879741A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
MX2019005192A (es) Compuestos de quinolina selectivamente sustituida.
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
PH12017500660A1 (en) Novel compositions, uses and methods for making them
EP1993560A4 (en) CANNABINOID RECEPTOR ANTAGONISTS / INVERSE AGONISTS TO TREAT OVERWEIGHT
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
UA113440C2 (xx) Сполуки тетрагідропіразолопіримідину
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
GB201017345D0 (en) Receptor antagonists
UA112514C2 (uk) АНТАГОНІСТИ C5aR
WO2012068529A3 (en) Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
TR201900071T4 (tr) Kontrollü Over Stimülasyonuna Yönelik Bileşim
NZ763528A (en) Heterocyclic gpr119 agonist compounds
PH12018502274A1 (en) Semaglutide in cardiovascular conditions
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
PH12015502523A1 (en) Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
EA026371B8 (ru) Индолкарбонитрилы в качестве модуляторов рецептора андрогенов
HK1257166A1 (zh) 作為大麻素受體2激動劑的苯基衍生物
MX364912B (es) Antagonistas / agonistas inversos del receptor canabinoide.

Legal Events

Date Code Title Description
FG Grant or registration